March 24, 2022 -- Artificial intelligence-powered spatial biology company Nucleai closed a $33 million series B financing round, which it will use to advance its spatial biology platform for drug research, development, and diagnostics.
The company said it plans to use the new funding to further develop its platform and expand its commercial footprint across biopharmaceutical companies and contract research organizations, which are applying Nucleai's technology throughout translational research, clinical trials, and novel applications for drug discovery.
The funding round was jointly led by Section 32 and Sanofi Ventures. Existing investors, including Debiopharm, Fosun RZ Capital, Vertex Ventures, and Grove Ventures, participated in this round, the company reported.
Copyright © 2022 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
